MAXCYTE, INC. — AGM Information 2019

Oct 8, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0594P

MaxCyte, Inc.

08 October 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notification of Annual General Meeting and Declaration of Audit Remuneration

Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.

These documents are also available in electronic form on the Company's website: www.maxcyte.com.

In order to assist investors in considering the resolutions proposed ahead of the AGM, the Company notes that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for audit-related services relating to the 2018 financial year, amounted to approximately $99,200.

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. EDT on 31 October 2019 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	+1 301 944 1660
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns	+44 (0)20 7886 2500
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	+44 (0)20 7260 1000
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji --------------------------------------------------------------	+44 (0)203 709 5700 [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NOAKDLFBKBFXFBK